MedTrace Logo

Myeloproliferative Neoplasms and Bone Structure

NCT01816022 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2013-03-21

No results posted yet for this study

Summary

This is a clinical study to evaluate the effect of CMPN (Chronic myeloproliferative neoplasm) to the bone.

The hypothesis is that patients with CMPN have a higher fracture-rate compared to the background population. We expect to find a lower BMD using conventional DXA scan (dual energy x-ray absorptiometry), and a change in other parameters using HR-pQCT (high-resolution peripheral quantitative computerized tomography).Biochemical bone markers is measured to support the hypothesis.

Conditions

Sponsors & Collaborators

  • University of Southern Denmark

    lead OTHER

Principal Investigators

  • Sarah Farmer, MD · Department of Hematology, Clinical Institute, University of Southern Denmark

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-03-31
Completion
2015-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01816022 on ClinicalTrials.gov